Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2011

Open Access 01-12-2011 | Research article

Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes

Authors: Kazutaka Sakamoto, Makoto Osaki, Akira Hozumi, Hisataka Goto, Tatsuya Fukushima, Hideo Baba, Hiroyuki Shindo

Published in: BMC Musculoskeletal Disorders | Issue 1/2011

Login to get access

Abstract

Background

Osteonecrosis of the femoral head is a common complication of high-dose glucocorticoid treatment. Intravascular thrombosis is thought to be associated with the ischemic state of the femoral head. Plasminogen activator inhibitor-1 (PAI-1) is an adipokine, which are physiologically active substances secreted from visceral and subcutaneous adipocytes. PAI-1 suppresses fibrinolysis by binding tissue-type plasminogen activator. Several reports have described the relationship between PAI-1 and steroid-induced osteonecrosis of the femoral head, and the preventive effects of lipid-lowering agents (statins) against steroid-induced osteonecrosis of the femoral head. We previously reported that adipokines and dexamethasone induced PAI-1 secretion from bone marrow adipocytes. The purpose of the present study is to examine the effects of simvastatin on PAI-1 secretion from human bone marrow adipocytes in vitro.

Methods

Primary bone marrow adipocytes were extracted from collagenase-treated bone marrow fluid obtained from the femoral necks of 40 patients (6 men, 34 women; age range, 52-81 years) undergoing hip joint replacement surgery. After suspended culture with or without dexamethasone or simvastatin, PAI-1 mRNA expression was assessed by real-time RT-PCR. Total PAI-1 protein secretion in culture medium was assessed by enzyme-linked immunosorbent assay.

Results

PAI-1 mRNA expression was up-regulated by 388% (P = 0.002) with dexamethasone, and down-regulated by 45% (P = 0.002) with simvastatin, as compared to control levels. Dexamethasone increased total PAI-1 secretion by 166% (P = 0.001) and simvastatin decreased total PAI-1 secretion by 64% (P = 0.002). No significant changes were observed in adiponectin mRNA expression and secretion by dexamethasone and simvastatin, while pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion by 89%, as compared to control levels.

Conclusion

The present study confirmed the suppressive effects of simvastatin on PAI-1 expression and secretion from bone marrow adipocytes. Furthermore, pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion. Simvastatin may thus exhibit preventive effects against steroid-induced osteonecrosis of the femoral head by suppressing PAI-1 secretion.
Appendix
Available only for authorised users
Literature
1.
Glueck CJ, Fontaine RN, Gruppo R, Stroop D, Sieve-Smith L, Tracy T, Wang P: The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999, 366: 133-146.CrossRefPubMed
2.
Posan E, Szepesi K, Gaspar L, Csernatony Z, Harsfalvi J, Ajzner E, Toth A, Udvardy M: Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral head. Blood Coagul Fibrinolysis. 2003, 14: 243-248.PubMed
3.
Mont MA, Ulrich SD, Seyler TM: Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis. J Rheumatol. 2007, 34: 466-468.PubMed
4.
Yin L, Li YB, Wang YS: Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chi Med J. 2006, 199: 581-588.
5.
Murata M, Kumagai K, Miyata N, Osaki M, Shindo H: Osteonecrosis in stroke-prone spontaneously hypertensive rats: effect of glucocorticoid. J Orthop Sci. 2007, 12: 289-295.CrossRefPubMed
6.
Kerachian MA, Seguin C, Harvey EJ: Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009, 114: 121-128.CrossRefPubMed
7.
Okada Y, Tanikawa T, Iida T, Tanaka Y: Vascular injury by glucocorticoid; involvement of apoptosis of endothelial cells. Clin Calcium. 2007, 17: 872-877.PubMed
8.
Motomura G, Yamamoto T, Miyanishi K, Yamashita A, Sueishi K, Iwamoto Y: Bone marrow fat-cell enlargement in early steroid-induced osteonecrosis--a histomorphometric study of autopsy cases. Pathol Res Pract. 2005, 200: 807-811.CrossRefPubMed
9.
Miyanishi K, Yamamoto T, Irisa T, Yamashita A, Jingushi S, Noguchi Y, Iwamoto Y: Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone. 2002, 30: 185-190.CrossRefPubMed
10.
11.
Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf). 2006, 64: 355-365.
12.
Hozumi A, Osaki M, Goto H, Sakamoto K, Inokuchi S, Shindo H: Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation. Biochem Biophys Res Commun. 2009, 382: 780-784.CrossRefPubMed
13.
Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007, 18: 263-270.CrossRefPubMed
14.
Alessi MC, Poggi M, Juhan-Vague I: Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007, 18: 240-245.CrossRefPubMed
15.
Miyanishi K, Kamo Y, Ihara H, Naka T, Hirakawa M, Sugioka Y: Risk factors for dysbaric osteonecrosis. Rheumatology (Oxf). 2006, 45: 855-858.CrossRef
16.
Kang P, Shen B, Yang J, Pei F: Circulating platelet-derived microparticles and endothelium-derived microparticles may be a potential cause of microthrombosis in patients with osteonecrosis of the femoral head. Thromb Res. 2008, 123: 367-373.CrossRefPubMed
17.
Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne BS: Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol. 1993, 44: 243-248.CrossRefPubMed
18.
Tan X, Cai D, Wu Y, Liu B, Rong L, Chen Z, Zhao Q: Comparative analysis of serum proteomes: discovery of proteins associated with osteonecrosis of the femoral head. Transl Res. 2006, 148: 114-119.CrossRefPubMed
19.
Hozumi A, Osaki M, Sakamoto K, Goto H, Fukushima T, Baba H, Shindo H: Dexamethasone-induced plasminogen activator inhibitor-1 expression in human primary bone marrow adipocytes. Biomedical Research. 2010, 31: 281-286.CrossRefPubMed
20.
Motomura G, Yamamoto T, Miyanishi K, Jingushi S, Iwamoto Y: Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Arthritis Rheum. 2004, 50: 3387-3391.CrossRefPubMed
21.
Pritchett JW: Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001, 173-178.
22.
Pengde K, Hong G, Fuxing P, Bin S, Jing Y, Zongke Z: Effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Int J Exp Path. 2010, 91: 235-243.CrossRef
23.
Pengde K, Fuxing P, Bin S, Jing Y, Jingqiu C: Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits. Joint Bone Spine. 2008, 75: 696-701.CrossRefPubMed
24.
Kitajima M, Shigematsu M, Ogawa K, Sugihara H, Hotokebuchi T: Effects of glucocorticoid on adipocyte size in human bone marrow. Med Mol Morphol. 2007, 40: 150-156.CrossRefPubMed
25.
Zhang G, Qin L, Sheng H, Wang XL, Wang YX, Yeung DK, Griffith JF, Yao XS, Xie XH, Li ZR, Lee KM, Leung KS: A novel semisynthesized small molecule icaritin reduces incidence of steroid-associated osteonecrosis with inhibition of both thrombosis and lipid-deposition in a dose-dependent manner. Bone. 2009, 44: 345-356.CrossRefPubMed
26.
Nishida K, Yamamoto T, Motomura G, Jingushi S, Iwamoto Y: Pitavastatin may reduce risk of steroid-induced osteonecrosis in rabbits. Clin Orthop Relat Res. 2008, 466: 1054-1058.CrossRefPubMedPubMedCentral
27.
Laumen H, Skurk T, Hauner H: The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008, 196: 565-573.CrossRefPubMed
28.
Li JQ, Zhao SP, Li QZ, Cai YC, Wu LR, Fang Y, Li P: Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits. Clin Chim Acta. 2006, 370: 57-62.CrossRefPubMed
29.
Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 1998, 83: 683-690.CrossRefPubMed
30.
Markle RA, Han J, Summers BD, Yokoyama T, Hajjar KA, Hajjar DP, Gotto AM, Nicholson AC: Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003, 90: 23-32.CrossRefPubMed
31.
Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, Tsuji H: HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res. 2003, 110: 227-234.CrossRefPubMed
32.
Sato Y, Dong J, Imagawa S, Ishimori N, Furumoto T, Tsutsui H, Sobel BE, Fujii S: Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1. Coron Artery Dis. 2008, 19: 355-361.CrossRefPubMed
33.
Kruithof EK: Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost. 2008, 100: 969-975.PubMed
34.
Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G: Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol. 1998, 9: 1377-1388.PubMed
35.
Ishibashi T, Nagata K, Ohkawara H, Sakamoto T, Yokoyama K, Shindo J, Sugimoto K, Sakurada S, Takuwa Y, Teramoto T, Maruyama Y: Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta. 2002, 1590: 123-130.CrossRefPubMed
36.
Iwakiri K, Oda Y, Kaneshiro Y, Iwaki H, Masada T, Kobayashi A, Asada A, Takaoka K: Effect of simvastatin on steroid-induced osteonecrosis evidenced by the serum lipid level and hepatic cytochrome P4503A in a rabbit model. J Orthop Sci. 2008, 13: 463-468.CrossRefPubMed
37.
Kaneshiro Y, Oda Y, Iwakiri K, Masada T, Iwaki H, Hirota Y, Kondo K, Takaoka K: Low hepatic cytochrome P4503A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther. 2006, 80: 396-402.CrossRefPubMed
38.
Horsmans Y, Desager JP, van den Berge V, Abrassart M, Harvengt C: Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res. 1993, 28: 243-248.
39.
Halleux CM, Servais I, Reul BA, Detry R, Brichard SM: Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: increased responsiveness to glucocorticoids in obesity. J Clin Endocrinol Metab. 1998, 83: 902-910.PubMed
40.
Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, Vidal-Puig A, Jones R, Considine RV: Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res. 2005, 13: 662-669.CrossRefPubMed
Metadata
Title
Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
Authors
Kazutaka Sakamoto
Makoto Osaki
Akira Hozumi
Hisataka Goto
Tatsuya Fukushima
Hideo Baba
Hiroyuki Shindo
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2011
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-12-82

Other articles of this Issue 1/2011

BMC Musculoskeletal Disorders 1/2011 Go to the issue

Research article

mtDNA haplogroup J Modulates telomere length and Nitric Oxide production

Research article

Semiquantitative assessment of subchondral bone marrow edema-like lesions and subchondral cysts of the knee at 3T MRI: A comparison between intermediate-weighted fat-suppressed spin echo and Dual Echo Steady State sequences

Research article

Genetic predisposition to fracture non-union: a case control study of a preliminary single nucleotide polymorphisms analysis of the BMP pathway

Research article

The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage

Research article

Transgenic overexpression of miR-133a in skeletal muscle

Research article

Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro